Watchlist

Watchlist
Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Inc. (ABEO)
Value And Momentum Breakouts - 2017 End Of Year Report Card And Forecast
Introduction The four categories of investment models offered in their entirety this past year to subscribers are detailed below. Each category represents very different models formed into consistent samples of portfolios both weekly and monthly for two reasons: (1) To test that the financia…
Relieving Suffering From Genetic Disease - Abeona Therapeutics
Investment Thesis Abeona Therapeutics ( ABEO ) is a well positioned company in the biotech space which has seen strong performance thus far in 2017 with even stronger potential in the coming year based on pipeline catalysts. They exist in a complex and well populated gene therapy market look…
Adverum: Preparing For Liftoff. The Next Abeona
The best risk/reward in Biotech in 2018-19: 30% downside versus 100x upside It is about 12 months since I first recommended Abeona ( ABEO ) as a deep value play in gene therapy and my top pick for 2017. With the stock up 300% since that initial report, it is time to look for 2018's money m…
Biotech: Biding Its Time
Biotech Pulse The months of October and November have been unfavorable for biotechs as the sector has witnessed a sharp pullback. The Nasdaq Biotechnology Index ( IBB ), shown below, retreated 12% from its 52-week high posted in early October. Nasdaq Biotechnology Index ETF ((IBB)) Dur…
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x…
Abeona Therapeutics' (ABEO) CEO Tim Miller on Q3 2017 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q3 2017 Earnings Conference Call November 20, 2017 10:00 AM ET Executives Christine Silverstein - Vice President, Investor Relations Tim Miller - President and Chief Executive Officer Jeff Davis - Chief Operating Officer Analysts Matthew Eckl…
Abeona Therapeutics (ABEO) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this Read more …
Abeona Therapeutics beats by $0.06, revenue in-line
Abeona Therapeutics (NASDAQ: ABEO ): Q3 EPS of -$0.13 beats by $0.06 . More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more …
Premarket analyst action - healthcare
PSivida (NASDAQ: PSDV ) initiated with Buy rating and $5 (331% upside) price target by Laidlaw citing bullish prospects for lead candidate Durasert. More news on: pSivida Corp., Abeona Therapeutics Inc., Omeros Corporation, Healthcare stocks news, Read more …
Your Daily Pharma Scoop: Johnson & Johnson's Mixed Signals, Celgene's Mongersen Failure, QURE's Hemophilia B Trial
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Johnson & Johnson Today we will discuss a set of…
Fibrocell Science: A Very Appealing Gene Therapy Play
Shares of Fibrocell Science ( FCSC ) have risen by over 50% year to date, but are still in the red by almost 70% over the past three years. FCSC data by YCharts Its surprising that a biotech company with such a small valuation (market capitalization currently hovering near $40 millio…
Abeona Therapeutics Inc. (ABEO)